Active substance
Carbetocin
- SFDA 2
- Health Canada 2
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Cotrax | 100 µg/ml | Solution for injection · Intravenous use | 4 Vial | SAR 234.40 | Generic · Prescription | KUWAIT SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
| PABAL RTS 100 mcg/ml Solution for Injection | 100 µ/ml | Solution for injection · Intramuscular and intravenous use | 5 Vial | SAR 333.50 | NCE · Prescription | FERRING | Valid |
Indications — CHI Daman Drug Formulary
MATERNAL AND CHILD HEALTHCARE- POSTPARTUM HEMORRHAGE
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CARBETOCIN INJECTION | 02489244 | 100 MCG / ML | SOLUTION · INTRAVENOUS | JUNO PHARMA CANADA INC. |
| DURATOCIN | 02496526 | 100 MCG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | FERRING INC |
WHO WHO Model List of Essential Medicines (2025)
- 22.3. Uterotonics · core
Postpartum haemorrhage
Parenteral > General injections > IV: 100 µg per mL (heat stable)
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.